Published in AIDS Res Ther on March 20, 2017
MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol (2011) 220.97
Clustal W and Clustal X version 2.0. Bioinformatics (2007) 126.47
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A (2000) 11.51
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62
Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science (1984) 10.38
Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science (1995) 10.02
Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood (2004) 7.09
Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med (1995) 6.50
Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol (2006) 6.30
Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res (2007) 5.95
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A (2007) 4.96
Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol (2006) 4.27
HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis (2005) 3.77
Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis (2009) 3.48
Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog (2012) 3.35
Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res Hum Retroviruses (1996) 3.01
A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences. AIDS Res Hum Retroviruses (1995) 2.78
A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol (2000) 2.68
Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol (1995) 2.68
Understanding the benign nature of SIV infection in natural hosts. J Clin Invest (2007) 2.43
Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis (2000) 2.36
Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog (2009) 2.36
The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev (2000) 2.36
Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol (2005) 2.25
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A (1997) 2.24
Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest (2003) 2.21
Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy. Clin Infect Dis (1999) 2.17
HIV-1 sequence variation: drift, shift, and attenuation. Cell (2001) 2.10
Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. J Virol (2004) 2.09
Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol (2000) 2.04
Natural SIV hosts: showing AIDS the door. Science (2012) 2.03
Grossly defective nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor. J Virol (1998) 1.99
Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol (2010) 1.80
Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS (2009) 1.74
Host factors in the pathogenesis of HIV disease. Immunol Rev (1997) 1.64
Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest (2011) 1.61
Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease. J Virol (1999) 1.61
Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist Updat (2002) 1.54
Role of the human immunodeficiency virus type 1 envelope gene in viral fitness. J Virol (2003) 1.51
Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis. PLoS Pathog (2012) 1.50
Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis (2010) 1.50
Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog (2009) 1.49
In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression. J Virol (1997) 1.48
Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes. J Clin Microbiol (2012) 1.45
Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C. J Virol (2011) 1.45
What can natural infection of African monkeys with simian immunodeficiency virus tell us about the pathogenesis of AIDS? AIDS Rev (2004) 1.43
Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol (2007) 1.35
Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J Clin Microbiol (2005) 1.34
Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS (1997) 1.32
Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers. J Acquir Immune Defic Syndr (2011) 1.27
Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. J Virol Methods (2006) 1.26
Virus fitness: concept, quantification, and application to HIV population dynamics. Curr Top Microbiol Immunol (2006) 1.25
Host and viral genetic correlates of clinical definitions of HIV-1 disease progression. PLoS One (2010) 1.23
The paradox of simian immunodeficiency virus infection in sooty mangabeys: active viral replication without disease progression. Front Biosci (2004) 1.22
First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection. Virology (2003) 1.12
The nef gene from a long-term HIV type 1 nonprogressor. AIDS Res Hum Retroviruses (1996) 1.11
Virological, immune and host genetics markers in the control of HIV infection. Dis Markers (2009) 1.10
Nonpathogenic simian immunodeficiency virus infections. Cold Spring Harb Perspect Med (2012) 1.08
Characterization of human immunodeficiency virus type 1 vif gene in long-term asymptomatic individuals. Virology (2000) 1.08
Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism. Antimicrob Agents Chemother (2014) 1.08
Identification of attenuated variants of HIV-1 circulating recombinant form 01_AE that are associated with slow disease progression due to gross genetic alterations in the nef/long terminal repeat sequences. J Infect Dis (2005) 1.07
Survival rate of AIDS disease and mortality in HIV-infected patients: a meta-analysis. Public Health (2016) 1.04
Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression. Proc Natl Acad Sci U S A (2015) 1.03
A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. J Gen Virol (2003) 1.02
HIV pathogenesis: the host. Cold Spring Harb Perspect Med (2012) 1.02
Limited HIV infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in viremic individuals. PLoS Pathog (2014) 1.01
Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations. J Virol (2005) 0.96
Disease Progression in HIV-1-Infected Viremic Controllers. J Acquir Immune Defic Syndr (2012) 0.95
Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. Front Immunol (2013) 0.92
Impaired nuclear import and viral incorporation of Vpr derived from a HIV long-term non-progressor. Retrovirology (2008) 0.92
Reduced fitness of HIV-1 resistant to CXCR4 antagonists. Antivir Ther (2003) 0.91
Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides. Antimicrob Agents Chemother (2011) 0.90
HIV-1 replicative fitness in elite controllers. Curr Opin HIV AIDS (2011) 0.88
Restriction Factors in HIV-1 Disease Progression. Curr HIV Res (2015) 0.87
Differential prevalence of the HLA-C -- 35 CC genotype among viremic long term non-progressor and elite controller HIV+ individuals. Immunobiology (2012) 0.85
Deletion, insertion and stop codon mutations in vif genes of HIV-1 infecting slow progressor patients. J Infect Dev Ctries (2009) 0.84
Alterations in HIV-1 LTR promoter activity during AIDS progression. Virology (2003) 0.84
Rate and predictors of progression in elite and viremic HIV-1 controllers. AIDS (2016) 0.83
Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy. Antimicrob Agents Chemother (2011) 0.83
Viral factors in non-progression. Front Immunol (2013) 0.82
Viremic HIV infected individuals with high CD4 T cells and functional envelope proteins show anti-gp41 antibodies with unique specificity and function. PLoS One (2012) 0.82
Prolonged control of an HIV type 1 escape variant following treatment interruption in an HLA-B*27-positive patient. AIDS Res Hum Retroviruses (2010) 0.81
Estimating the fitness cost of escape from HLA presentation in HIV-1 protease and reverse transcriptase. PLoS Comput Biol (2012) 0.81
Genetic analysis of the long terminal repeat (LTR) promoter region in HIV-1-infected individuals with different rates of disease progression. Virus Genes (2006) 0.80
Unusual substitutions in HIV-1 vif from children infected perinatally without progression to AIDS for more than 8 years without therapy. J Med Virol (2012) 0.80
Biological phenotypes of HIV-1 in pathogenesis and transmission. Antibiot Chemother (1971) (1994) 0.79
Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy. PLoS One (2014) 0.78
PAPNC, a novel method to calculate nucleotide diversity from large scale next generation sequencing data. J Virol Methods (2014) 0.78
Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection. Sci Transl Med (2016) 0.77
Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals. AIDS Res Ther (2017) 0.75
Chikungunya Virus' High Genomic Plasticity Enables Rapid Adaptation to Restrictive A549 Cells. Viruses (2022) 0.75
Characterization of the First SARS-CoV-2 Isolates from Aotearoa New Zealand as Part of a Rapid Response to the COVID-19 Pandemic. Viruses (2022) 0.75